RT Journal Article
SR Electronic
T1 RT-qPCR half reaction optimization for the detection of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257470
DO 10.1101/2021.05.19.21257470
A1 Wink, Priscila Lamb
A1 Volpato, Fabiana
A1 de Lima-Morales, Daiana
A1 Paiva, Rodrigo Minuto
A1 Willig, Julia Biz
A1 Bock, Hugo
A1 de Paris, Fernanda
A1 Luís Barth, Afonso
YR 2021
UL http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257470.abstract
AB BACKGROUND The main laboratory test for the diagnosis of COVID-19 is the reverse transcription real-time polymerase chain reaction (RT-qPCR). However, the RT-qPCR is an expensive method due to the number of tests required.OBJECTIVES To evaluate an alternative RT-qPCR approach for the detection of SARS-CoV-2 sing half of the total volume currently recommended by the US Centers for Disease Control and Prevention.METHODS The analytical limit of detection (LoD) and the reaction efficiency using half volumes of RT-qPCR assay were evaluated for both the N1 and N2 regions by using a synthetic control RNA. A panel of 76 SARS-CoV-2-positive and 26 SARS-CoV-2-negative clinical samples were evaluated to establish the clinical sensitivity and specificity.FINDINGS The RT-qPCR assay efficiency was 105% for both the half and standard reactions considering the N2 target and 84% (standard) and 101% (half) for N1. The RT-qPCR half reaction LoD for N1 and N2 were 20 and 80 copies/µL, respectively. Clinical sensitivity and specificity were 100%. The half reaction presented a decrease of up to 5.5 cycle thresholds when compared with the standard RT-qPCR.CONCLUSIONS The use of RT-qPCR half reaction proved to be a feasible and economic strategy for detection of SARS-CoV-2 RNA.Sponsorship This work was supported by FAPERGS (20/2551-0000265-9) and by Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE/HCPA) (Project no. 2020-0163).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementThis work was supported by FAPERGS (20/2551-0000265-9) and by Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clinicas de Porto Alegre (FIPE/HCPA) (Project no. 2020-0163).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committees from Hospital de Clinicas de Porto Alegre (CAAE: 30767420.2.0000.5327).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.